Cytek Biosciences (CTKB) to Release Earnings on Wednesday

Cytek Biosciences (NASDAQ:CTKB) is expected to be releasing its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect Cytek Biosciences to post earnings of $0.01 per share and revenue of $51.4880 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Cytek Biosciences (NASDAQ:CTKB) last released its quarterly earnings data on Tuesday, November 28th. The company reported $0.04 earnings per share (EPS) for the quarter. Cytek Biosciences had a negative return on equity of 1.66% and a negative net margin of 3.27%.The firm had revenue of $40.48 million during the quarter.

Cytek Biosciences Price Performance

Shares of CTKB stock opened at $4.20 on Wednesday. Cytek Biosciences has a fifty-two week low of $2.37 and a fifty-two week high of $7.63. The stock’s 50-day moving average is $3.94 and its two-hundred day moving average is $3.59. The firm has a market cap of $534.32 million, a P/E ratio of -84.00 and a beta of 1.31.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CTKB. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytek Biosciences in a research report on Wednesday, October 8th. Zacks Research raised shares of Cytek Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $5.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CTKB. Topline Capital Management LLC raised its holdings in Cytek Biosciences by 255.7% in the 2nd quarter. Topline Capital Management LLC now owns 5,231,260 shares of the company’s stock worth $17,786,000 after acquiring an additional 3,760,485 shares during the period. AQR Capital Management LLC increased its stake in shares of Cytek Biosciences by 89.6% in the second quarter. AQR Capital Management LLC now owns 1,238,393 shares of the company’s stock worth $4,211,000 after purchasing an additional 585,116 shares during the period. Ameriprise Financial Inc. lifted its position in shares of Cytek Biosciences by 48.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 412,311 shares of the company’s stock worth $1,402,000 after purchasing an additional 134,963 shares during the last quarter. Public Sector Pension Investment Board boosted its stake in Cytek Biosciences by 5.7% during the 2nd quarter. Public Sector Pension Investment Board now owns 349,736 shares of the company’s stock valued at $1,189,000 after purchasing an additional 18,822 shares during the period. Finally, Jane Street Group LLC grew its holdings in Cytek Biosciences by 412.2% in the 1st quarter. Jane Street Group LLC now owns 344,169 shares of the company’s stock valued at $1,380,000 after buying an additional 276,972 shares during the last quarter. 69.46% of the stock is currently owned by institutional investors and hedge funds.

About Cytek Biosciences

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.